Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
โ
of holders' portfolios
13F filers
0
institutions
Market cap
$284.1M
63M shares
52-week range
$1.41 โ $7.75
49% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
www.camp4tx.comNo one on the platform currently holds CAMP.
No tracked institution reports a position in CAMP as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-02-02 | 1-for-23reverse |
No one on the platform has traded CAMP yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CAMP Heeeerrrre weeeeee gooooooooo!!!!!
View on StockTwits โ$CAMP Another amazing day!! Let's keep up the fantastic work. See you all at $6 ๐๐๐
View on StockTwits โ$CAMP BIG NEWS!!!!! Sign the deal $NVDA nooowwwwwww ๐๐๐๐๐๐๐
View on StockTwits โ$CAMP ๐ข Bullish filings: โ CEO: 6,551 shares โ CFO: 6,551 โ CMO: 6,551 โ Director: 16,378 โ 5AM Ventures: 3,179,558 pre-funded warrant shares Total: 3,215,589 shares / about $4.92M committed. No insider selling. Management and a major backer are increasing exposure they they know the integration of AI into its therapeutic medicine platform will cause the stock to go up ๐๐๐๐๐
View on StockTwits โ$CAMP CEO purchased 6,551 shares at $1.65 for a total of $10,809. Mandel-Brehm Josh now owns 284,968 shares. https://ceo-buys.com
View on StockTwits โ$CAMP Let's also not forget the big picture here. News of major partnerships and future deals are coming.
View on StockTwits โ$CAMP -As of the first quarter of 2026, the company reported about $99.2 million in cash and stated this is expected to fund operations into 2028 and reducing near-term financing pressure...
View on StockTwits โ$CAMP this is actually holding up way better than I thought
View on StockTwits โ$CAMP what did I tell you all!!!!! Congrats to all the longs.
View on StockTwits โ$CAMP HERE WE GOOOOOOOOOOOOOOO ๐๐๐๐๐๐๐๐๐๐๐๐๐๐๐๐๐
View on StockTwits โ$CAMP It's the kind of catalyst that can lead to a higher valuation because it: โ๏ธ Removes a major regulatory hurdle โ๏ธ Brings in significant funding โ๏ธ Moves the lead program into human trials ๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐
View on StockTwits โ$CAMP Earnings next month as well. Keep an eye on $CAMP
View on StockTwits โ$CAMP Already up 7% on news. Also, this is huge clinical stage validity.
View on StockTwits โRecent $TICKER stream from stocktwits.com โ refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $6M | +75.2% | $-0.81 | $-1.01โ$-0.66 | โ | 5 |
| 2027 | $6M | -6.2% | $-0.73 | $-0.93โ$-0.49 | โ | 5 |
| 2028 | $2M | -70.5% | $-0.78 | $-0.97โ$-0.49 | โ | 6 |
| 2029 | $12M | +579.6% | $-0.74 | $-1.19โ$-0.07 | โ | 3 |
Forward consensus ยท growth is YoY vs the prior fiscal-year estimate ยท Fwd P/E at the current price ยท source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.21 | $-0.22 | -4.1% |
| 2026-05-07 | $-0.21 | $-0.32 | -52.4% |
| 2026-03-05 | $-0.31 | $-0.87 | -180.6% |
| 2025-11-06 | $-0.47 | $-0.55 | -17.0% |
| 2025-08-14 | $-0.67 | $-0.62 | +7.5% |
| 2025-05-13 | $-0.70 | $-0.62 | +11.4% |
| 2025-03-27 | $-0.91 | $-0.77 | +15.4% |
| 2025-02-20 | $-0.82 |
| $-24.19 |
| -2850.0% |
| $93M |
| โ |
| HYFTMindWalk Holdings Corp. | $1.39 | +6.11% | $65M | โ |
| PMVPPMV Pharmaceuticals, Inc. | $1.22 | -3.57% | $65M | โ |
Source: Financial Modeling Prep ยท peers by sector/industry